Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
Type:
Application
Filed:
January 15, 2002
Publication date:
March 13, 2003
Applicant:
Innogenetics N.V.
Inventors:
Robert DeLeys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswij
Abstract: The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04new and HLA-DRB4*01new are disclosed. The present invention also relates to methods of typing of such alleles. According to a particular embodiment, typing of alleles is achieved by: i) amplifying a relevant fragment of the alleles with at least one suitable set of primers; ii) hybridizing the amplification product of step i) to at least one probe that specifically hybridizes to a target region comprising one or more polymorphic nucleotides in said relevant fragment; and iii) determining from the result of step ii) the absence or presence of the alleles in the sample. The present invention further provides primers and probes to be used in such methods of typing alleles. Diagnostic kits comprising such primers and probes are also included within the invention.
Abstract: Described is a new variety of retrovirus designated HIV-3, also known as HIV-1 subtype O, samples of which are deposited in the European Collection of Animal Cell Cultures (ECACC) under V88060301. Further described is a process to detect the HIV-3 retrovirus in biological liquids or tissue. One such process involves contacting a biological sample suspected of containing HIV-3 nucleic acids with a DNA probe corresponding to a segment of genomic HIV-3 retrovirus RNA, such as the LTR region, and detecting the hybridization products thereof.
Type:
Application
Filed:
May 9, 2001
Publication date:
February 27, 2003
Applicant:
Innogenetics N.V.
Inventors:
Robert De Leys, Bart Vanderborght, Eric Saman, Hugo Van Heuverswyn
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:
Type:
Application
Filed:
July 6, 2001
Publication date:
February 20, 2003
Applicant:
Innogenetics N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
Type:
Application
Filed:
July 6, 2001
Publication date:
February 20, 2003
Applicant:
INNOGENETICS N.V.
Inventors:
Geert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
Abstract: Antibodies to two new epitopes on the HCV envelope proteins we, identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.
Type:
Grant
Filed:
August 24, 2000
Date of Patent:
February 18, 2003
Assignee:
Innogenetics N.V.
Inventors:
Geert Maertens, Erik Depla, Marie-Ange Buyse
Abstract: The claimed invention relates to an HIV-1 group O envelope antigen comprising SEQ ID NO: 100, and the use of said antigen as a reagent in the diagnosis of HIV-1 group O infection, and a kit therefore.
Type:
Grant
Filed:
April 3, 2000
Date of Patent:
January 28, 2003
Assignee:
Innogenetics, N.V.
Inventors:
Eric DeLaporte, Martine Peeters, Eric Saman, Marleen Vanden Haesevelde
Abstract: A method for the diagnosis of brain/neurological disease involving abnormally phosphorylated tau protein using at least one antibody chosen from the group consisting of monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul.
Type:
Grant
Filed:
November 2, 1999
Date of Patent:
December 31, 2002
Assignee:
Innogenetics N.V.
Inventors:
Marc Vandermeeren, Eugeen Vanmechelen, André Van De Voorde
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:
contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position −291 to nucleotide at position −66 of the 5′ untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes,
detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV i
Type:
Grant
Filed:
August 23, 1999
Date of Patent:
December 17, 2002
Assignee:
Innogenetics, N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2I, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:
Type:
Application
Filed:
July 6, 2001
Publication date:
November 14, 2002
Applicant:
Innogenetics N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.
Type:
Application
Filed:
January 24, 2002
Publication date:
November 7, 2002
Applicant:
INNOGENETICS N.V.
Inventors:
Lydie Meheus, Reinhard Georg Luhrmann, Ann Union, Joseph Raymackers
Abstract: The present invention provides an alternative PCR amplification which does not draw upon the use of thermostable DNA polymerases. It provides means for the controlled manipulation of denaturing conditions which do not demand the use of high denaturing temperature. More particularly, it provides means for the controlled oscillation of divalent metal ions, preferably of divalent metal ions such as Cu 2+, Zn 2+, Mn 2+ and Cd 2+, which are known to destabilize the DNA helix and thereby decrease the melting temperature of the DNA helix. The invention also provides methods for the automatization of this process. For instance, by means of cathodic reduction of the divalent metal species the concentration can be decreased to levels that allows for reannealing of separated strands with the primers; while oxidation of deposited metals or oxidation of monovalent metal ions, can restore the initially high concentration that allows for separation of both strands that make up the DNA helix.
Abstract: Transfusion of contaminated blood has become the major route of transmission for Chagas' disease. Current screening tests are insensitive and yield conflicting results, while confirmatory assays do not exist. The present invention relates to antigens and their use for serological diagnosis of Chagas' disease. More specifically, the present invention concerns assays which are able to reliably and accurately detect the presence of antibodies to various specific antigens of Trypanosoma cruzi in a highly sensitive and specific manner.
Abstract: The present invention relates to a composition comprising a biopolymer matrix comprising cross-linked vinyl-derivatives of gelatin, or co-polymerized methacrylamide modified gelatin with vinyl-modified polysaccharides, or cross-linked vinyl-substituted polysaccharide and gelatin being physically entrapped in a semi-interpenetrating network. Preferably said polysaccharide comprises dextran or xanthan. The present invention also relates to a wound dressing or a controlled release device comprising said biopolymer matrix. Preferably said matrix is in the form of a hydrated film, a hydrated or dry foam, dry fibers which may be fabricated into a woven or non-woven tissue, hydrated or dry microbeads, dry powder, or covered with a semipermeable film so as to control the humidity of the wound covered with the dressing, with the permeability chosen so as to maintain this humidity within a therapeutically optimal window.
Type:
Grant
Filed:
January 28, 2000
Date of Patent:
October 1, 2002
Assignee:
Innogenetics N.V.
Inventors:
Etienne Schacht, An Van Den Bulcke, Bernard Delaey, Jean-Pierre Draye
Abstract: A sensor for identifying molecular structures within a sample solution is disclosed. The sensor comprises an insulating layer with a plurality of interspaced channels therein having essentially the same direction. The channels furthermore have submicron dimensions. A method of fabricating a sensor for identifying molecular structures within a sample solution is also disclosed.
Type:
Grant
Filed:
May 3, 1999
Date of Patent:
August 27, 2002
Assignee:
Innogenetics N.V.
Inventors:
Peter Van Gerwen, Kris Baert, Rudi Rossau
Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
Type:
Application
Filed:
August 30, 2001
Publication date:
August 8, 2002
Applicant:
Innogenetics N.V.
Inventors:
Robert J. Deleys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn
Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of:
Type:
Application
Filed:
July 6, 2001
Publication date:
August 8, 2002
Applicant:
Innogenetics N.V.
Inventors:
Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
Abstract: The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
March 26, 2002
Assignee:
Innogenetics N.V.
Inventors:
Lydie Meheus, Ann Union, Joseph Raymackers, Reinhard Georg Lührmann
Abstract: The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.